Glenmark Pharmaceuticals Q3 Results 2025:Glenmark Pharmaceuticals declared their Q3 results on 14 Feb, 2025, revealing a ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin ...

Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and ...

India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

Glenmark Pharmaceuticals reported a significant profit of Rs 348 crore for Q3 2024, rebounding from a Rs 351 crore loss in ...

The company reported a loss of Rs 351 crore in the comparable quarter last year, hurt by sluggish sales in India and charges ...

Glenmark Pharmaceuticals reports strong revenue growth and expansion plans for dermatology and respiratory portfolios in ...

Glenmark Pharmaceuticals reported a consolidated profit after tax of Rs 348 crore in Q3 FY25, driven by strong regional ...

EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter.  Shares of Glenmark ...

Glenmark Pharmaceuticals on Friday said its consolidated profit after tax stood at Rs 348 crore for the third quarter ended ...

Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY. Revenue ...

Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically ...